Close monitoring and early intervention: management principles for cystic fibrosis in Denmark.
Tavs QvistBibi Uhre NielsenHanne Vebert OlesenInger Hee Mabuza MathiesenDaniel Faurholt-JepsenTerese L KatzensteinJannik Helweg-LarsenFrederikke RönsholtMajbritt JeppesenMette Frahm OlsenFrederik Fouirnaies BuchvaldKim Gjerum NielsenSøren Jensen-FangelTania PresslerMarianne SkovPublished in: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica (2024)
Cystic fibrosis (CF) care in Denmark has been characterized by close monitoring and pre-emptive treatment of lung disease and other CF-related complications. Continuous evaluation through data collection and commitment to clinical research has incrementally improved outcomes. This approach has been in line with best practices set forth by European Standards of Care but has also gone beyond Society standards particularly pertaining to early treatment with high-dose combination antimicrobial therapy. Despite a high prevalence of severe CF variants, lung function has been among the best in Europe. In this review, the Danish approach to management of CF prior to the introduction of new CF modulator treatment is explained and benchmarked. Downsides to the Danish approach are discussed and include increased burden of treatment, risk of antimicrobial resistance, side-effects and costs.
Keyphrases
- cystic fibrosis
- lung function
- pseudomonas aeruginosa
- high dose
- antimicrobial resistance
- palliative care
- randomized controlled trial
- primary care
- stem cells
- machine learning
- skeletal muscle
- chronic obstructive pulmonary disease
- big data
- bone marrow
- early onset
- insulin resistance
- mesenchymal stem cells
- artificial intelligence
- pain management
- stem cell transplantation
- gene expression